Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
2011

Levothyroxine Monotherapy and Euthyroidism in Athyreotic Patients

Sample size: 6816 publication Evidence: moderate

Author Information

Author(s): Gullo Damiano, Latina Adele, Frasca Francesco, Le Moli Rosario, Pellegriti Gabriella, Vigneri Riccardo

Primary Institution: University of Catania Medical School, Garibaldi-Nesima Hospital, Catania, Italy

Hypothesis

Can levothyroxine monotherapy normalize serum thyroid hormones and thyroid-pituitary feedback in athyreotic patients?

Conclusion

Athyreotic patients show a heterogeneous capacity to produce T3 from levothyroxine, with over 20% not maintaining normal FT3 or FT4 levels despite normal TSH.

Supporting Evidence

  • 15.2% of levothyroxine-treated patients had lower serum FT3 levels than normal.
  • 7.2% had higher serum FT4 levels compared to euthyroid controls.
  • 29.6% of patients had FT3/FT4 ratios lower than the normal range.

Takeaway

Some people who take thyroid medicine might not feel better because their bodies can't turn the medicine into the hormone they really need.

Methodology

Retrospective analysis of serum TSH, FT4, and FT3 levels in athyreotic patients under levothyroxine treatment compared to euthyroid controls.

Potential Biases

Potential biases due to the observational nature of the study.

Limitations

The study is retrospective and may have unrecognized confounders.

Participant Demographics

1,811 athyreotic patients (1,530 females, 281 males) and 3,875 euthyroid controls (3,224 females, 651 males).

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0022552

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication